Rewards Hub Sonnet BioTherapeutics, a Nasdaq-listed biotechnology firm, has received shareholder approval for its merger with Hyperliquid Strategies, Inc. The merger will result in Sonnet changing its name to Hyperliquid Strategies. As part of the transaction, the company is expected to hold 12.6 million HYPE tokens and $300 million in cash, marking a significant strategic shift for the biotech company.
Sonnet BioTherapeutics Secures Shareholder Approval for Merger with Hyperliquid Strategies
Disclaimer: The content provided on Phemex News is for informational purposes only. We do not guarantee the quality, accuracy, or completeness of the information sourced from third-party articles. The content on this page does not constitute financial or investment advice. We strongly encourage you to conduct you own research and consult with a qualified financial advisor before making any investment decisions.